Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms

Sponsor
Duke University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05739955
Collaborator
University of North Carolina (Other)
918
1
3
36
25.5

Study Details

Study Description

Brief Summary

The purpose of this study is to determine if enhanced daily application of disinfectant with persistent 24-hour activity decreases the environmental bioburden compared to standard practice.

Condition or Disease Intervention/Treatment Phase
  • Other: Sani24
  • Other: Standard EPA-registered disinfectant
  • Other: Routine Disinfection
N/A

Detailed Description

The study investigator will evaluate the effectiveness of daily disinfection strategies on environmental contamination in acute care hospital rooms.

The trial will be conducted in acute care hospital rooms at Duke University Hospital, Duke Regional Hospital, Duke Raleigh Hospital, and the University of North Carolina Medical Center. In each study room, one half will be randomized to the control arm, and the other half will be randomized to one of the two intervention arms. Two separate randomization steps will occur. First, each room will be randomized to Intervention 1 or Intervention 2. Second, the half of the room to which the intervention will be applied (e.g., right vs. left) will be randomly selected. The control arm will receive no interventions. Rooms randomized to the control arm will undergo routine disinfection via existing Environmental Services (EVS) protocols. All study hospitals routinely use EPA-registered disinfectants for low-level disinfection of hospital room surfaces. Intervention 1 is the standard EPA-registered disinfectant to each study surface and will be applied by the study team. Intervention 2 is a quaternary ammonium, salt-based, 24-hour continuously active germicidal wipe (Sani-24®) to each study surface and will be applied by the study team.

Three different methods will be used for disinfection. No changes to baseline and routine disinfection practices will occur during the study. EVS employees at study hospitals will be responsible for the total room cleaning and disinfection throughout the study. Tasks will be separated between study team members to maintain blinding.Room contamination will be measured before the application of the interventions on study day 1 and every 24 hours for 3 subsequent days, for a total of 4 days. Secondary outcomes include evaluation for epidemiologically important pathogens (EIP), including me staphylococcus aureus (MRSA or MSSA), extended spectrum beta-lactamase (ESBL) or carbapenem-resistant Enterobacteriaceae (CRE) producing Enterobacterales, vancomycin-resistant Enterococci (VRE), vancomycin-susceptible Enterococci (VSE), Acinetobacter spp., and Pseudomonas aeruginosa.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
918 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Each participant's inpatient room are enrolled in one of the interventions and control arms at the same time.Each participant's inpatient room are enrolled in one of the interventions and control arms at the same time.
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
Triple blind - exception of the study team member applying the disinfectant products (intervention 1 or 2)
Primary Purpose:
Basic Science
Official Title:
Determining the Impact of Enhanced Daily Disinfection on Environmental Contamination in Acute Care Hospital Rooms: A 3-arm Multicenter Blinded Randomized Controlled Trial
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2026
Anticipated Study Completion Date :
Feb 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sani24

Application of a 24-hour continuously acting quaternary ammonium salt disinfectant: Sani24 (PDI Healthcare Inc.) by study team

Other: Sani24
24-hour continuously acting quaternary ammonium salt disinfectant

Experimental: Standard EPA-registered disinfectant

Application of standard EPA-registered disinfectant by study team

Other: Standard EPA-registered disinfectant
Standard EPA-registered disinfectant

Active Comparator: Control

Routine disinfection completed by hospital staff

Other: Routine Disinfection
Routine disinfection at the study hospital

Outcome Measures

Primary Outcome Measures

  1. Change in total room contamination in study rooms on study day 2 [Baseline (day 1), day 2]

    Total contamination, in colony-forming units (CFUs) on environmental surfaces on study days 1 and 2

Secondary Outcome Measures

  1. Change in total room contamination [Day 2, Day 3, Day 4]

    Total CFU measured on study days 2, 3, and 4

  2. Frequency of daily disinfection by EVS or unit personnel (control arm) and study personnel (intervention arms) [Day 2, Day 3, Day 4]

    Proportion of sample areas with removed ultraviolet glowing gel on study days 2, 3, 4

  3. Total room contamination with epidemiologically important pathogens (EIP) [Day 1, Day 2, Day 3, Day 4]

    Number of samples positive for individual EIP

  4. Total contamination on room bed rails [Day 1, Day 2, Day 3, Day 4]

    Total CFU measured from room bed rails on study days 1, 2, 3, 4

  5. Total contamination on room footboards [Day 1, Day 2, Day 3, Day 4]

    Total CFU measured from room footboards on study days 1, 2, 3, 4

  6. Total contamination on room sinks [Day 1, Day 2, Day 3, Day 4]

    Total CFU measured from room sinks on study days 1, 2, 3, 4

  7. Total EIP contamination on room bed rails [Day 1, Day 2, Day 3, Day 4]

    Total EIP measured from room bed rails on study days 1, 2, 3, 4

  8. Total EIP contamination on room footboards [Day 1, Day 2, Day 3, Day 4]

    Total EIP measured from room footboards on study days 1, 2, 3, 4

  9. Total EIP contamination on room sinks [Day 1, Day 2, Day 3, Day 4]

    Total EIP measured from room sinks on study days 1, 2, 3, 4

  10. Proportion of positive environmental cultures [Day 1, Day 2, Day 3, Day 4]

    Frequency of growth of any organism on any of the surfaces and on each surface.

  11. Proportion of EIP positive environmental cultures [Day 1, Day 2, Day 3, Day 4]

    Frequency of EIP growth on any of the surfaces and on each surface.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patient admitted to the room

  • Patient spent ≥1 night in room prior to enrollment

  • Anticipated patient stay of ≥48 hours

  • On contact precautions (for any reason) and/or has positive culture for EIP at the time of room admission

Exclusion Criteria:
  • Patient stay is expect to be <48 hours

  • Patient age <18, even if on adult ward

  • Patient admitted on respiratory precautions due to coronavirus disease (COVID-19), influenza, or respiratory syncytial virus (RSV)

  • Patient on contact precautions due to C. difficile

Contacts and Locations

Locations

Site City State Country Postal Code
1 Duke Univeristy Durham North Carolina United States 27710

Sponsors and Collaborators

  • Duke University
  • University of North Carolina

Investigators

  • Principal Investigator: Deverick Anderson, MD, Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT05739955
Other Study ID Numbers:
  • Pro00112526
First Posted:
Feb 22, 2023
Last Update Posted:
Feb 22, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Duke University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 22, 2023